Media coverage about Mesa Laboratories (NASDAQ:MLAB) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesa Laboratories earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 46.4825867243182 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several brokerages have commented on MLAB. Zacks Investment Research cut shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Friday, November 10th. TheStreet upgraded shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research report on Monday, November 6th.

Shares of Mesa Laboratories (NASDAQ:MLAB) traded up $1.60 during mid-day trading on Wednesday, reaching $128.20. 9,300 shares of the company’s stock were exchanged, compared to its average volume of 15,807. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.86 and a quick ratio of 1.97. The company has a market cap of $478.52, a P/E ratio of 33.49 and a beta of 0.41. Mesa Laboratories has a twelve month low of $113.57 and a twelve month high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the Zacks’ consensus estimate of $0.64 by ($0.04). The company had revenue of $22.95 million during the quarter, compared to the consensus estimate of $25.50 million. Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. analysts expect that Mesa Laboratories will post 2.47 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.50%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 23.10%.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with's FREE daily email newsletter.